We are now here... and all bets are on the table!
www.InvestorStemCell.com
Donate
Page 1 of 3 1 2 3 LastLast
Results 1 to 20 of 58
Like Tree56Likes

Thread: We are now here... and all bets are on the table!

  1. #1
    Experience
    Points: 56,840, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 51.0%
    Achievements:
    Social Created Blog entry Tagger First Class 1 year registered Your first Group
    Awards:
    Posting Award
    Ceasar de Cuenca's Avatar
    Join Date
    Apr 2011
    Posts
    3,005
    Location
    California
    Country: United States
    Blog Entries
    38
    Likes Given: 1252
    Likes Received: 15120

    We are now here... and all bets are on the table!

    I am sure that Lanza, Mickunas, Rabin, and Bill Caldwell are all as excited as I am considering
    the events that will be unfolding in the coming months.

    Last night, I spent many hours going back over our patents, published materials, conference presentations,
    videos, and comments on a very specific topic. And, this is the engraftment of the RPE Cells on the BM.
    I was looking at the characteristics of the RPE Cell surfaces, the influence of integrin, and the age and the health of the BM... all, and everything and as much studies/trial information in animals and humans, as these influence the engraftment process of the RPE Cells into the BM.

    This is the heart of ACTC's trials.

    This morning and most of today, I am still looking for any negative data that will make me doubt or change my mind in regards to my confidence that ACTC will be successful.

    Off course, I know that anything can go wrong!

    On the other hand, if there is any team, anywhere, who knows this issue... It is Lanza's team.

    But, I want to make sure... for my own peace of mind.

    So, I reviewed our RPE patents, and Wow! Many times, and this patent is worth much much more than
    one can imagine. Reviewed, again, the pre-clinical studies and animal models, reviewed other studies involving cadaver RPEs, fetal RPEs, and adult RPEs... and its engraftment results and issues...

    And hell! after many hours... I still could not find any data that will dampen my judgement call that ACTC is very close to a home run.

    And yes, if there are any PHDs around who will tell me that something can still go wrong... I agree.
    But heck, anything can go wrong on anything, any day... but I am not talking about this kind
    of statistical probability.

    I just had a very nice Reserva Chianti from Tuscany and a double cappuccino...
    and I am mellow.

    I suppose I have done looking at all the possible things that can go wrong... and I am ok.

    I am happy.

    Best and just making sure,
    Cuenca

  2. #2
    Experience
    Points: 5,896, Level: 49
    Level completed: 73%, Points required for next Level: 54
    Overall activity: 28.0%
    Achievements:
    1 year registered Tagger First Class 5000 Experience Points
    bo-bo241's Avatar
    Join Date
    Apr 2011
    Posts
    705
    Location
    Northwest Coast, Oregon
    Country: United States
    Likes Given: 2646
    Likes Received: 1034
    Today is my 4th year anniversary owning ACT stock and quite happy about all progress and sugested outcomes. Really looking forward to this years events. I am hoping that indeed OHSU is one of the sites. It is a great teaching hospital and right next door to Casey Eye Institute, where the rat tests were done. I'm Oregonian and proud to be on this threshold, best to all of us and ACT.

  3. #3
    Experience
    Points: 5,923, Level: 49
    Level completed: 87%, Points required for next Level: 27
    Overall activity: 8.0%
    Achievements:
    Social Tagger First Class 1 year registered 5000 Experience Points
    BioDigger's Avatar
    Join Date
    Apr 2011
    Posts
    365
    Location
    Western Washington State
    Country: United States
    Likes Given: 352
    Likes Received: 705
    Well, Cuenca, I had a personal experience today. Had my eye exam and was informed that my AMD had advanced in the past three years. I can't see anything different yet but my MD says it is advancing and that I will go blind eventually. He knows about ACT and said that their stem cell treatment would NOT help my type of AMD. He did say other companies were working on AMD treatments that would apply. That was the first time I had heard there might be different forms of AMD and that not all were stem-cell treatable. I posted a rather long post earlier today but it seems to have disappeared. At least I can't find it. But it is that kind of 'surprise' that bothers me, it is the shot from left field because it can cause treatment "failures" and we all know what that will do to the PPS. Guess we'll see if this post makes it past the monitors.

    BD

  4. #4
    Experience
    Points: 7,230, Level: 56
    Level completed: 40%, Points required for next Level: 120
    Overall activity: 22.0%
    Achievements:
    Social Tagger First Class 1 year registered 5000 Experience Points
    stemedga's Avatar
    Join Date
    Apr 2011
    Posts
    1,550
    Location
    Metro Atlanta
    Country: United States
    Likes Given: 12654
    Likes Received: 2655
    Ceasar,
    I support all what you say here. We are not perfect in what we do in the lab. That is why it is research. These trials are perhaps the greatest event since the invention of the wheel. People scream why don't the trials start already..... This is the most scrutinized event and rightly so, for they are crossing every T and checking and rechecking. Patience and you have just stated why. The ACT Lanza Team will not accept failure.

  5. #5
    Experience
    Points: 887, Level: 15
    Level completed: 87%, Points required for next Level: 13
    Overall activity: 0%
    Achievements:
    3 months registered 500 Experience Points
    bobo's Avatar Colleague Member
    Join Date
    Apr 2011
    Posts
    82
    Location
    New York
    Country: United States
    Likes Given: 38
    Likes Received: 24
    Ceasar,
    Reserva Chianti from Tuscany, a double cappuccino, and your sure Bill Caldwell is as excited as you are. I'll have some of that Chianti, and cappuccino please. lol. Thanks again Ceasar for your insightful analysis of the facts.
    bobo
    chumptochamp likes this.

  6. #6
    Experience
    Points: 1,132, Level: 18
    Level completed: 32%, Points required for next Level: 68
    Overall activity: 0%
    Achievements:
    Tagger Second Class 1 year registered 1000 Experience Points
    allmar's Avatar Participant Member
    Join Date
    Apr 2011
    Posts
    60
    Location
    Florida USA
    Country: United States
    Likes Given: 36
    Likes Received: 29
    I agree with the analysis.

  7. #7
    Achievements:
    Social 3 months registered Tagger First Class 1000 Experience Points
    Bullard's Avatar Banned
    Join Date
    Apr 2011
    Posts
    120
    Country: United States
    Likes Given: 98
    Likes Received: 180
    Thanks for sharing your perspective Ceasar. Uncertainty is embedding is in the fabric of everything but the failure of the RPE cells to graft appears remote. My analysis is more focused on degree of success (i.e. - at what point in the progression of the disease will the RPE cells show improvement and to what degree?). The answer to that question will probably determine if we're a $2 billion cap company or a $100 billion cap company in the next five years.

  8. #8
    Experience
    Points: 4,674, Level: 43
    Level completed: 62%, Points required for next Level: 76
    Overall activity: 8.0%
    Achievements:
    Tagger First Class 1000 Experience Points 1 year registered Social
    Harlem's Avatar
    Join Date
    Apr 2011
    Posts
    326
    Location
    nj
    Country: United States
    Likes Given: 1327
    Likes Received: 531
    Glad to see your post!!! thank you

  9. #9
    eigenman
    eigenman's Avatar Guest
    Likes Given:
    Likes Received:
    Quote Originally Posted by Bullard View Post
    Thanks for sharing your perspective Ceasar. Uncertainty is embedding is in the fabric of everything but the failure of the RPE cells to graft appears remote. My analysis is more focused on degree of success (i.e. - at what point in the progression of the disease will the RPE cells show improvement and to what degree?). The answer to that question will probably determine if we're a $2 billion cap company or a $100 billion cap company in the next five years.
    Keep in mind that the researchers of the BM paper 2 months ago said in an email they have a method that they believe will help attachment in the severely damaged BM cases.
    Attachment is the key here and it sounds like it will only get better.
    DMSOB, Bullard, TonyaW and 4 others like this.

  10. #10
    Experience
    Points: 1,978, Level: 26
    Level completed: 78%, Points required for next Level: 22
    Overall activity: 2.0%
    Achievements:
    Tagger Second Class 1000 Experience Points 1 year registered
    great-grandma's Avatar
    Join Date
    Apr 2011
    Posts
    143
    Location
    Davenport FL
    Country: United States
    Likes Given: 1087
    Likes Received: 263
    Thanks, Caesar, for all the work you do. I always look forward to your posts.

  11. #11
    Experience
    Points: 237,384, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    Social Tagger First Class 1 year registered 50000 Experience Points
    jckrdu's Avatar
    Join Date
    Apr 2011
    Posts
    1,692
    Country: United States
    Likes Given: 5226
    Likes Received: 6893
    I believe the Phase I safety trials will be a homerun, and I believe we'll see some level of engraftment of the RPE cells in the early Phase 1 results. I do like that Rabin is working to set expectations via his statement in his recent email where he wrote: "Certainly, the patient selection of the first cohorts in the trials, particularly of the AMD patients (who will tend to be elderly with severely deteriorated sight) may impact our engraftment viability."

    I'm still not 100% certain when younger Dry AMD patients with better sight and a higher probability of viable engraftment will start to be enrolled. Do we have to wait until the first 12 patients (over 55 with severely deteriorated sight) get all the way thru Phase I before younger patients are enrolled? That's my understanding.

  12. #12
    Experience
    Points: 237,384, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    Social Tagger First Class 1 year registered 50000 Experience Points
    jckrdu's Avatar
    Join Date
    Apr 2011
    Posts
    1,692
    Country: United States
    Likes Given: 5226
    Likes Received: 6893
    Quote Originally Posted by jckrdu View Post
    I believe the Phase I safety trials will be a homerun, and I believe we'll see some level of engraftment of the RPE cells in the early Phase 1 results. I do like that Rabin is working to set expectations via his statement in his recent email where he wrote: "Certainly, the patient selection of the first cohorts in the trials, particularly of the AMD patients (who will tend to be elderly with severely deteriorated sight) may impact our engraftment viability."

    I'm still not 100% certain when younger Dry AMD patients with better sight and a higher probability of viable engraftment will start to be enrolled. Do we have to wait until the first 12 patients (over 55 with severely deteriorated sight) get all the way thru Phase I before younger patients are enrolled? That's my understanding.

    I'll talk to myself a little here: On the other hand, Rabin's statement specifically states that patients in the "first cohorts" will be elderly with deteriorated sight. To me, that implies that patients in the later cohorts will have better sight. So maybe after results are in for the first 2 cohorts (patients 1-6) we'll start enrolling younger patients with better sight?
    Actc_fan likes this.

  13. #13
    Experience
    Points: 240,901, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 77.0%
    Achievements:
    Social Tagger First Class 1 year registered 50000 Experience Points
    Actc_fan's Avatar
    Join Date
    Apr 2011
    Posts
    2,768
    Country: United States
    Likes Given: 6571
    Likes Received: 7023
    Quote Originally Posted by jckrdu View Post
    I'll talk to myself a little here: On the other hand, Rabin's statement specifically states that patients in the "first cohorts" will be elderly with deteriorated sight. To me, that implies that patients in the later cohorts will have better sight. So maybe after results are in for the first 2 cohorts (patients 1-6) we'll start enrolling younger patients with better sight?
    Your guess is as good as mine, but that would make sense to me. Once they are seeing good safety results in the first few patients, I would think they would want to test the limits of both halting progression of the disease and trying to demonstrate improvement. I imagine improvement might come easier in patients with less damage. JMHO

  14. #14
    Experience
    Points: 237,384, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    Social Tagger First Class 1 year registered 50000 Experience Points
    jckrdu's Avatar
    Join Date
    Apr 2011
    Posts
    1,692
    Country: United States
    Likes Given: 5226
    Likes Received: 6893
    Quote Originally Posted by Actc_fan View Post
    Your guess is as good as mine, but that would make sense to me. Once they are seeing good safety results in the first few patients, I would think they would want to test the limits of both halting progression of the disease and trying to demonstrate improvement. I imagine improvement might come easier in patients with less damage. JMHO
    I think that's the way it will go. I was getting hung-up on the entry criteria posted on clintrials.gov, and was working under the assumption that it was static. I now believe that after safety results are validated for the first 2 cohorts, we'll see an update to the entry criteria on clintrials.gov where we'll be able to enroll younger patients with better sight. This all makes sense as this is a combined Phase I/Phase II study.... and Phase II is testing for efficacy..... and in order to test for efficacy you need to enroll younger patients at earlier stages of the disease.

  15. #15
    Experience
    Points: 3,225, Level: 35
    Level completed: 17%, Points required for next Level: 125
    Overall activity: 10.0%
    Achievements:
    Social 3 months registered Tagger First Class 1000 Experience Points
    ACT4me's Avatar Omniscient Member
    Join Date
    Apr 2011
    Posts
    469
    Location
    The Big Smoke
    Country: Canada
    Likes Given: 370
    Likes Received: 398
    Salut !! C.C

  16. #16
    Experience
    Points: 7,339, Level: 56
    Level completed: 95%, Points required for next Level: 11
    Overall activity: 0%
    Achievements:
    Tagger First Class 1 year registered 5000 Experience Points
    adventurous's Avatar Delegate Member
    Join Date
    Apr 2011
    Posts
    188
    Location
    California
    Country: United States
    Likes Given: 60
    Likes Received: 131
    Please everyone keep in mind that when there is news on safety results of Phase I trials that if there is no mention of improved vision do not be disappointed. I think some people are under the assumption that these older cohorts will regain some vision. While apparently possible, the YES/NO of the clinical trial is SAFETY and not effectiveness.

    So when results come out simply stating that there's no adverse reaction, but no mention of improved vision, do not be disappointed. You may even see a drop in pps due to many people expecting a miracle. Case in point: Geron. They released patient 1 had no adverse side effects. The stock didn't skyrocket. In my opinion it was phenomenal news, but the market only wants to hear about efficacy and not safety.

    Just my .02c
    DMSOB, Jcsantos, BioDigger and 2 others like this.

  17. #17
    Experience
    Points: 1,842, Level: 25
    Level completed: 43%, Points required for next Level: 58
    Overall activity: 1.0%
    Achievements:
    Tagger Second Class 1 year registered 1000 Experience Points
    Mtn Man's Avatar
    Join Date
    Apr 2011
    Posts
    33
    Location
    Tahoe
    Country: United States
    Likes Given: 34
    Likes Received: 55
    Quote Originally Posted by jckrdu View Post
    I'll talk to myself a little here: On the other hand, Rabin's statement specifically states that patients in the "first cohorts" will be elderly with deteriorated sight. To me, that implies that patients in the later cohorts will have better sight. So maybe after results are in for the first 2 cohorts (patients 1-6) we'll start enrolling younger patients with better sight?
    The enrollment criteria is here Search of: MA09-hRPE - List Results - ClinicalTrials.gov for both trials AMD and SMD.

    AMD 55 years or older
    SMD 18 years or older

    The question I have is, are we looking for the same attachment to the BM for both AMD and SMD? If so, then we may get to see an attachment difference between older and younger BMs. Maybe, SMD and AMD are too disparate to compare across the two studies.......

    If any of our in-house Dr. can review some of the eligibility criteria it would be interesting to hear their thoughts.

    Mtn Man

  18. #18
    eigenman
    eigenman's Avatar Guest
    Likes Given:
    Likes Received:
    Quote Originally Posted by Mtn Man View Post
    The enrollment criteria is here Search of: MA09-hRPE - List Results - ClinicalTrials.gov for both trials AMD and SMD.

    AMD 55 years or older
    SMD 18 years or older

    The question I have is, are we looking for the same attachment to the BM for both AMD and SMD? If so, then we may get to see an attachment difference between older and younger BMs. Maybe, SMD and AMD are too disparate to compare across the two studies.......

    If any of our in-house Dr. can review some of the eligibility criteria it would be interesting to hear their thoughts.

    Mtn Man
    I'd like to know how damaged young Stargardt's patients' BM's are compared with people with AMD. I know as you get older AMD can damage the BM more and more, but I don't have any data on the BM's of Stargardt's patients. Are the BM's in good or bad shape at a young age?

  19. #19
    Experience
    Points: 237,384, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 18.0%
    Achievements:
    Social Tagger First Class 1 year registered 50000 Experience Points
    jckrdu's Avatar
    Join Date
    Apr 2011
    Posts
    1,692
    Country: United States
    Likes Given: 5226
    Likes Received: 6893
    Quote Originally Posted by Mtn Man View Post
    The enrollment criteria is here Search of: MA09-hRPE - List Results - ClinicalTrials.gov for both trials AMD and SMD.

    AMD 55 years or older
    SMD 18 years or older

    The question I have is, are we looking for the same attachment to the BM for both AMD and SMD? If so, then we may get to see an attachment difference between older and younger BMs. Maybe, SMD and AMD are too disparate to compare across the two studies.......

    If any of our in-house Dr. can review some of the eligibility criteria it would be interesting to hear their thoughts.

    Mtn Man
    Mtn Man - Yes, I saw the enrollment criteria. See my subsequent post where I state my belief that clintrials.gov and the enrollment criteria will be updated after the first 2 cohorts report satisfactory safety data. My thought is that we'll see the enrollment ages reduced after cohorts 1-2 so younger patients are enrolled to test for efficacy in this combined Phase I/II study. On your second question, I suspect we'll see better RPE engraftment in the SMD patients for cohorts 1-2, but an eye doc is better to respond to that question.

  20. #20
    Experience
    Points: 2,147,527,571, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 26.0%
    Achievements:
    Social Recommendation First Class 1 year registered Created Blog entry Tagger First Class
    Superfeeed's Avatar
    Join Date
    Feb 2011
    Posts
    4,239
    Location
    Martha's Vineyard
    Country: United States
    Blog Entries
    21
    Likes Given: 4948
    Likes Received: 9978
    Quote Originally Posted by BioDigger View Post
    Well, Cuenca, I had a personal experience today. Had my eye exam and was informed that my AMD had advanced in the past three years. I can't see anything different yet but my MD says it is advancing and that I will go blind eventually. He knows about ACT and said that their stem cell treatment would NOT help my type of AMD. He did say other companies were working on AMD treatments that would apply. That was the first time I had heard there might be different forms of AMD and that not all were stem-cell treatable. I posted a rather long post earlier today but it seems to have disappeared. At least I can't find it. But it is that kind of 'surprise' that bothers me, it is the shot from left field because it can cause treatment "failures" and we all know what that will do to the PPS. Guess we'll see if this post makes it past the monitors.

    BD
    Biodigger, can you PM me your eye docs name so I can send him an email. He is obviously not understanding you or you did not provide him the correct information. I am thinking Dr. Lund knows a bit more about the RPE cells ACT is using and so is not the some odd 25 Opthamologist members iCELL has. BTW what kind of AMD do you have wet or dry?

    thanks

    SF
    No Idea can succeed except at the expense of endurance; having a hand in easing the suffering of millions is worth the pain of not knowing if we were right all along or just dreamers of a world where friends and family suffer no more.

Page 1 of 3 1 2 3 LastLast

Tags for this Thread